The Global Hypophosphatasia Treatment Market is driven by increase in rare disease prevalence
The global hypophosphatasia treatment market has witnessed significant growth due to the increase in prevalence of rare diseases and growing awareness about orphan drugs. Hypophosphatasia is a rare genetic disorder characterized by defective bone and tooth development due to low activity of the enzyme alkaline phosphatase. Symptoms range from pain and seizures to respiratory failure depending on the severity. The currently approved treatment options include Asfotase alfa enzyme replacement therapy and bone transplantation. Asfotase alfa is the first approved treatment for hypophosphatasia commercialized by Kyowa Kirin as Strensiq which aids bone mineralization by increasing alkaline phosphatase levels.
The hypophosphatasia treatment market is estimated to be valued at USD 2.79 Bn in 2024 and is expected to reach USD 3.97 Bn by 2031, growing at a compound annual growth rate (CAGR) of 5.15% from 2024 to 2031.
The rising prevalence rates globally especially in North America and Europe along with increased diagnosis have boosted the demand for effective treatment options for Hypophosphatasia Treatment Market.
Get More Insights On - Hypophosphatasia Treatment Market
Get this Report in Japanese Language: 低ホスファターゼ症治療市場
Get this Report in Korean Language: 저인산염 결핍증 치료 시장
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian